Advocacy
Breakthrough T1D
Type 1 Diabetes
Research
Global Development
100

She is currently Breakthrough T1D's Chief Global Advocacy Officer.

Who is Lynn Star.

100

The year Breakthrough T1D, then called JDF (the Juvenile Diabetes Foundation), was founded.

What is 1970. (Specifically May 21)

100

By making too little (or none) of this, people with Type 1 need to rely on an external source of this molecule which is typically produced in the pancreas.

What is Insulin. 

100

Funded in part by JDRF (now Breakthrough T1D), this FDA drug has been shown to delay the onset of Type 1 for up to 3 years.

What is Tzield or Teplizumab.

100

These are the five primary revenue generating areas that fall under Global Development.

What are 1. Campaign, 2. Leadership Giving, 3. Corporate Giving, 4. Legacy Giving, 5. Field Operations.

200

This program provides $160 million annually to the National Institutes of Health (NIH) for type 1 diabetes (T1D) research.

What is the Special Diabetes Program or SDP.

200

Along with Powering Progress, these represent our three strategic priorities.

What are Raise More Funds, Activate Volunteers, and Advance Therapies.
Will also accept: FY25 - advance breakthroughs, unlock access, deepen engagement & support.

200

Also known as C₆H₁₂O₆, this sugar molecule is at the heart of Type 1 Diabetes.

What is Glucose.

200

These two types of therapies represent our "most promising approaches" according to Aaron.

What are Cell and Disease Modifying (therapies).

200

These programs fall under Breakthrough T1D's P2P umbrella.

What are 1. Walk, 2. Ride, 3. Marathon (or Endurance), 4. DIY.

300

This yearly Advocacy event is still a major Breakthrough T1D initiative, despite more than 1/2 of those newly diagnosed being older than 18.

What is children's congress.

300

This is the percentage of money raised that should go 'directly towards our mission' according to publicly available documents.

What is 80%.

300

These two elements create a 'closed loop system' common among those with Type 1 Diabetes. 

What are a Continuous Glucose Monitor (CGM) and an Insulin Pump.

300

This represents the 'Stage' at which most people are diagnosed with T1D (although with early detection we are trying to change this).

What is Stage 3. Clinical Diagnosis based on HbA1c.

300

This is the current phase of Breakthrough T1D's  campaign, which lasts until midway through FY26 when it will be launched publicly.

What is the Quiet Phase.

400

These two broad categories represent how Global Advocacy is structured.

What are 1. Health Policy & Regulatory Affairs, 2. Government Relations & Grass Roots Advocacy. 

400

These are the affiliates of Breakthrough T1D.

What are 1. Australia, 2. Canada, 3. Israel, the 4. Netherlands, 5. United Kingdom.

400

Diabetic retinopathy, diabetic macular edema, cataracts, and glaucoma are diseases which affect people with T1D at higher rates and impact this organ.

What is the Eye or Eyeball.

400

These are the three things the Research department considers when evaluating where to invest our dollars. (Hint; think 'potential')

What are 1) Therapeutic  2) Development 3) Market.

400

This represents the incredible donation total expected to be generated during Breakthrough T1D's campaign between now and FY29.

What is $1.4 Billion.

500

These 3 elements are covered by Breakthrough T1D's Coverage2Control Campaign.

What is 1) keeping out-of-pocket costs for insulin and diabetes management tools predictable and reasonable, 2) giving people the freedom to choose the insulin pump that’s right for them; and 3) covering all life-saving technology, including artificial pancreas systems.

500

In September 2022 this first of it's kind data simulation tool was launched, planting the flag that Breakthrough T1D had a truly global focus. 

What is The T1D Index.

500

According to the Endocrine society, this represents the range to keep your glucose between. (Hint; think time in range)

What is 70 to 180 mg/dL. Note, this can vary person by person.

500

This PhD scientist is the current Chief Research Officer at Breakthrough T1D.

Who is Dr. Sanjoy Dutta.

500

This is the Cost Per Dollar Raised (CPDR) that Breakthrough T1D would like to achieve by FY29.

What is .15 or 15 cents to raise $1.